vTv Therapeutics (NASDAQ:VTVT) Issues Quarterly Earnings Results, Beats Expectations By $1.44 EPS

vTv Therapeutics (NASDAQ:VTVT) released its quarterly earnings results on Wednesday. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44, Zacks reports. The firm had revenue of $36.84 million for the quarter, compared to analysts’ expectations of $20.00 million.

vTv Therapeutics Price Performance

Shares of NASDAQ:VTVT traded down $0.44 during trading on Wednesday, reaching $31.67. 43,048 shares of the company’s stock traded hands, compared to its average volume of 51,935. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The company has a 50 day moving average of $35.96 and a 200-day moving average of $33.87.

Institutional Investors Weigh In On vTv Therapeutics

Institutional investors have recently modified their holdings of the business. 683 Capital Management LLC acquired a new position in vTv Therapeutics during the 4th quarter valued at about $731,000. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics during the 4th quarter valued at about $221,000. Institutional investors own 17.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. BTIG Research reaffirmed a “buy” rating and set a $49.00 price target on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Friday, March 27th. Roth Mkm began coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price for the company. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Evercore began coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.